Navigation Links
Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development
Date:5/6/2008

Acquisition of dermal filler product enhances company's aesthetic portfolio

CORAL GABLES, Fla., May 6 /PRNewswire/ -- Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, announced today that it has acquired ABR Invent and ABR Development, developers of the dermal filler Atlean(R).

Stiefel will acquire all shares of ABR Invent and ABR Development through a definitive stock purchase agreement. Both ABR Invent and ABR Development are legal entities based in France.

"Stiefel Laboratories has been looking for the right dermal filler to add to our aesthetic portfolio for quite some time," said Charles W. Stiefel, chairman and CEO, Stiefel Laboratories. "After conducting due diligence and extensive research, our team made an offer to ABR Development, a company whose innovation, expertise and product portfolio will significantly strengthen our position in the global aesthetics market. We are delighted that our proposal was accepted."

Atlean(R) dermal filler is currently commercialized in France and Italy and distribution and manufacturing agreements for the product will remain in place throughout Europe. All sales representatives formerly employed by ABR Development will now become employees of Stiefel Laboratories.

Over the next 18 months, Stiefel plans to launch Atlean(R) dermal filler in multiple areas, including parts of Europe, Asia Pacific, Latin America and the Caribbean. The company will continue clinical development of Atlean(R) dermal filler in order to expeditiously submit the product for approval from the Food and Drug Administration (FDA) and other regulatory bodies around the world. Stiefel also expects to develop other products from the ABR portfolio.

According to Bill Humphries, president, Stiefel Laboratories, the company is optimistic that Atlean(R) dermal filler will be approved globally in key aesthetic markets.

"The use of dermal fillers is gr
'/>"/>

SOURCE Stiefel Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Stiefel Laboratories Appoints First Chief Scientific Officer
2. Stiefel Laboratories, Inc. Appoints New President
3. Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment
4. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Fourth Quarter Earnings
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
7. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Lawsuits Against Several Companies for Patent Infringement
8. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Third Quarter Earnings
9. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
10. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
Breaking Medicine News(10 mins):Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3
...ight and friendly 7-year-old at Shaughnessy Elemen... fatal bacterial meningitis disease//. She had...l. But later when her parents tried to wake her up...o die of the disease in Massachusetts since 2003....
...drenaline rush at Disneyland Paris, though now, it...ird-flu storm//. Ruffled up, Disney land Paris is ...ad swan. This is especially unwelcome news, as pan...’ Force, spotted a dead swan in the adventure park...
...dermatologists have warned about increased exposur...been found that Vitamin D//, produced by the skin ...the risk of cancer. With increase in the number of... Vitamin D levels in the body can be increased by...
...ganization, Biomedical Tissue Services has been ac...uneral home in Brooklyn and distributing it to var... is said to have contracted HIV following transpla...cervical fusion surgery (bone graft implantation i...
...pill. But lately it is has been listed in the top ...sin officials identified Ambien in the bloodstream...here are signs that Ambien-related driving arrests...F.D.A) Susan Cruzan said the drug's current label ...
...als trust is going to cut off nearly 300 jobs afte...rmula that incurred huge losses. //Royal Cornwall ...hat is amounting to debts of ?8.1 million which m...cause it works on the logic that it costs much les...
Other Medicine News:Health News:Sunlight Exposure Reduces Risk Of Breast, Prostate And Colon Cancer 2Health News:HIV Infected Body Parts Stolen: Biomedical Tissue Services To Face Legal Action 2Health News:Ambien Plus Alcohol Has A Bad Influence on the Drivers 2
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
(Date:12/3/2009)WILMINGTON, Del., Dec. 3 ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, will host a free webinar on Wednesday, Dec. 9, on the FDA,s dra
Breaking Medicine Technology:Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Natural and Organic Consumers Focus on Health and Wellness Amidst Public Health Concerns 61152 1Natural and Organic Consumers Focus on Health and Wellness Amidst Public Health Concerns 61152 2K State program will give young professionals skills to protect water resources 10693 1High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 1High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 2High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 3High Altitude Mountaineer Will Cross Joins Tender 26apos 3Bs HealthiFeet Team to Raise Awareness On Foot Care for People Battling Diabetes 61149 4
...Host Conference Call at 9:00 a.m. EDT-, MONTVALE,...aq: MEMY ) today announced top-line data from the...ontrolled Phase 2a study,of MEM 1003, a neuronal L...sease. The trial enrolled 183 subjects with mild t...in the United States and included monotherapy,subj...
...N.J. and NEW YORK, Oct. 12 Daiichi Sankyo,Inc. an...d today that they,have signed a contract for a co-...hi Sankyo,s AZOR(TM), a fixed combination of two,a...odipine and the,angiotensin receptor blocker, olme... letter of intent for the co-promotion agreement o...
Other Medicine Technology:Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 2Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 4Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 2Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 3Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM) 4
Microalbumin Linearity Control
Total IgE Control
Lyophilized Lipid Control
High-sensitive CRP Control
Medicine Products: